The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

Expensive clinical trials and few drug approvals can drive up drug prices for consumers.

Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.

With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.

Paola Arlotta seeks to understand the complex symphony of brain development in vitro by using organoid models.

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

The researcher who helped develop an Alzheimer's treatment now in clinical trials warns that the compound may actually impair memory.

The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes of luck.

EU and Africa plan co-operation on drug development

US FDA user fees may have accelerated new drug development but a recent survey suggests difficulties in obtaining volunteers for human clinical trials still slow progress.